Novel rna-biomarker signature for diagnosis of prostate cancer
AssigneeFraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
InventorsFriedemann Horn, Jörg Hackermüller, Sabina Christ, Kristin Reiche, Manfred Wirth, Michael Fröhner, Susanne Füssel
Life of this patent
Estimating the term…
Abstract
The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.
Claims12
A method for the diagnosis of prostate cancer, comprising the steps of
- a) analysing the expression levels of at least two nucleic acids in a sample of a patient, wherein said at least two nucleic acids are selected from at least two groups of nucleic acids, wherein said groups consist of:
- Group 1:
- SEQ ID NO 1
- Group 2:
- a splice variant of Ensembl gene ID ENSG00000245750.3 selected from the group consisting of SEQ ID NO:
- 4, 5, 6, 7, 8, 9 and 10
- Group 3:
- a splice variant of Ensembl gene ID ENSG00000255545.3 selected from the group SEQ ID NO:
- 26, 27, 28 and 29
- Group 4:
- SEQ ID NO 3 and 11
- Group 5:
- SEQ ID NO 12
- Group 6:
- SEQ ID NO 24
- Group 7:
- SEQ ID NO 36
- Group 8:
- SEQ ID NO 38
- b) wherein, if the expression level of said at least two nucleic acids is above a defined threshold value, the sample is designated as prostate cancer positive.
A method according to any of the preceding claims, wherein the analysis of the expression level is performed by measuring the fluorescence of a labelled primer, labelled probe or a fluorescent detection agent.
A method according to any of the preceding claims, wherein the analysis of the expression level is performed by qRT-PCR.
A kit for the diagnosis of prostate cancer comprising at least two primers or probes, which hybridize under stringent conditions to at least two nucleic acids, wherein said at least two nucleic acids are selected from at least two groups of nucleic acids, wherein said groups consist of:
- Group 1:
- SEQ ID NO 1
- Group 2:
- a splice variant of Ensembl gene ID ENSG00000245750.3 selected from the group consisting of SEQ ID NO:
- 4, 5, 6, 7, 8, 9 and 10
- Group 3:
- a splice variant of Ensembl gene ID ENSG00000255545.3 selected from the group SEQ ID NO:
- 26, 27, 28 and 29
- Group 4:
- SEQ ID NO 3 and 11
- Group 5:
- SEQ ID NO 12
- Group 6:
- SEQ ID NO 24
- Group 7:
- SEQ ID NO 36
- Group 8:
- SEQ ID NO 38
A method for the diagnosis and treatment of prostate cancer, comprising the steps of
- a. analysing the expression levels of at least two nucleic acids in a sample of a patient, wherein said at least two nucleic acids are selected from at least two groups of nucleic acids, wherein said groups consist of:
- Group 1:
- SEQ ID NO 1
- Group 2:
- a splice variant of Ensembl gene ID ENSG00000245750.3 selected from the group consisting of SEQ ID NO:
- 4, 5, 6, 7, 8, 9 and 10
- Group 3:
- a splice variant of Ensembl gene ID ENSG00000255545.3 selected from the group SEQ ID NO:
- 26, 27, 28 and 29
- Group 4:
- SEQ ID NO 3 and 11
- Group 5:
- SEQ ID NO 12
- Group 6:
- SEQ ID NO 24
- Group 7:
- SEQ ID NO 36
- Group 8:
- SEQ ID NO 38
- b. wherein, if the expression level of said at least two nucleic acids is above a defined threshold value, the sample is designated as prostate cancer positive;
- and
- c. administering to the patient one or more Prostate Cancer Therapeutic Agents.
Dependencies are inferred from the claim text.